​

Capricor Therapeutics (CAPR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CAPR Stock Forecast

Capricor Therapeutics (CAPR) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $45.00, with a high of $60.00 and a low of $13.00. This represents a 65.56% increase from the last price of $27.18.

- $12 $24 $36 $48 $60 High: $60 Avg: $45 Low: $13 Last Closed Price: $27.18

CAPR Stock Rating

Capricor Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

CAPR Price Target Upside V Benchmarks

TypeNameUpside
StockCapricor Therapeutics65.56%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts568
Avg Price Target$51.40$45.00$39.25
Last Closing Price$27.18$27.18$27.18
Upside/Downside89.11%65.56%44.41%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 2528---10
Nov, 2537---10
Oct, 2537---10
Sep, 2537---10
Aug, 2537---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 10, 2025Piper Sandler$45.00$27.3864.35%65.56%
Dec 08, 2025Oppenheimer$54.00$26.89100.82%98.68%
Dec 04, 2025Maxim Group$50.00$25.1898.57%83.96%
Dec 03, 2025Industrial Alliance Securities$48.00$27.7972.72%76.60%
Dec 03, 2025H.C. Wainwright$60.00$29.95100.33%120.75%
Nov 11, 2025Boobalan PachaiyappanRoth Capital$13.00$6.20109.68%-52.17%
Jul 11, 2025Edward TenthoffPiper Sandler$20.00$7.66161.10%-26.42%
Jul 11, 2025Joseph PantginisH.C. Wainwright$24.00$7.64214.14%-11.70%
Oct 21, 2024Edward TenthoffPiper Sandler$17.50$9.4385.58%-35.61%
Oct 14, 2024Leland GershallOppenheimer$21.50$8.89141.84%-20.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 10, 2025Piper SandlerOverweightOverweighthold
Dec 08, 2025OppenheimerOutperformOutperformhold
Dec 03, 2025Alliance Global PartnersBuyBuyhold
Dec 03, 2025H.C. WainwrightBuyBuyhold
Nov 11, 2025Roth CapitalBuyBuyhold
Jul 14, 2025Alliance Global PartnersBuyBuyhold
Jul 11, 2025Piper SandlerOverweightOverweighthold
Jul 11, 2025H.C. WainwrightBuyBuyhold
Jun 26, 2025B. RileyBuyinitialise
Jun 11, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.87$-0.84$-1.18$-0.83$-1.15----
Avg Forecast$-0.88$-0.80$-1.22$-1.04$-1.19$-0.98$0.41$1.25$3.48
High Forecast$-0.64$-0.58$-0.59$-0.87$-0.64$2.04$1.63$2.20$5.07
Low Forecast$-1.06$-0.96$-2.51$-1.21$-1.35$-1.90$-1.20$-0.94$2.07
Surprise %-1.14%5.00%-3.28%-20.19%-3.36%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$310.25K$244.90K$2.55M$25.18M$22.27M----
Avg Forecast$252.00K$222.50K$1.59M$21.05M$20.97M$44.47M$113.29M$184.74M$287.81M
High Forecast$291.47K$257.35K$2.89M$28.47M$21.45M$60.14M$113.29M$189.52M$389.25M
Low Forecast$198.26K$175.05K$960.35K$14.47M$20.66M$30.58M$113.29M$179.97M$197.92M
Surprise %23.12%10.07%59.84%19.62%6.21%----

Net Income Forecast

$-100M $-50M $0 $50M $100M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-13.48M$-19.41M$-29.02M$-22.29M$-40.47M----
Avg Forecast$-23.56M$-21.42M$-32.58M$-27.85M$-34.11M$-40.14M$18.31M$16.87M$93.10M
High Forecast$-17.03M$-15.48M$-15.73M$-23.31M$-17.12M$54.74M$43.65M$58.91M$135.75M
Low Forecast$-28.36M$-25.79M$-67.10M$-32.39M$-36.08M$-50.88M$-32.13M$-25.17M$55.30M
Surprise %-42.80%-9.40%-10.93%-19.97%18.63%----

CAPR Forecast FAQ

Is Capricor Therapeutics stock a buy?

Capricor Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Capricor Therapeutics is a favorable investment for most analysts.

What is Capricor Therapeutics's price target?

Capricor Therapeutics's price target, set by 9 Wall Street analysts, averages $45 over the next 12 months. The price target range spans from $13 at the low end to $60 at the high end, suggesting a potential 65.56% change from the previous closing price of $27.18.

How does Capricor Therapeutics stock forecast compare to its benchmarks?

Capricor Therapeutics's stock forecast shows a 65.56% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Capricor Therapeutics over the past three months?

  • December 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Capricor Therapeutics’s EPS forecast?

Capricor Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.98, marking a -14.78% decrease from the reported $-1.15 in 2024. Estimates for the following years are $0.41 in 2026, $1.25 in 2027, and $3.48 in 2028.

What is Capricor Therapeutics’s revenue forecast?

Capricor Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $44.47M, reflecting a 99.67% increase from the reported $22.27M in 2024. The forecast for 2026 is $113.29M, followed by $184.74M for 2027, and $287.81M for 2028.

What is Capricor Therapeutics’s net income forecast?

Capricor Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-40.142M, representing a -0.80% decrease from the reported $-40.467M in 2024. Projections indicate $18.31M in 2026, $16.87M in 2027, and $93.1M in 2028.